Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tianjin Binhai New Area To Invest RMB 10 Billion In Pharmaceutical Industry

This article was originally published in PharmAsia News

Executive Summary

The Tianjin Binhai New Area will invest RMB 10 Billion ($146 million) over the next five years to set up an international-standard biopharmaceutical infrastructure and incubator in its 10-square-kilometer biopharmaceutical industrialization demonstration area. Expected to start operation in 2010, the public technology platform's core areas include a clinical trial platform, a drug testing and analysis center, the Tianjin National Biomedical Industry Base and good laboratory practice-compliant drug safety assessment center. To attract global and renowned local enterprises and R&D institutions, Binhai is establishing a biopharmaceutical industry development fund of RMB 5 billion and will allocate some RMB 100 million per year to support new drug R&D transfer. Project leaders can apply for subsidies of up to RMB 10 million based on the scale and R&D phase. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072632

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel